Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

One of the world’s most widely used anti-malarial drugs is safe to use, say researchers, after a thorough review and analysis of nearly 200,000 malaria patients who’d taken the drug dihydroartemisinin-piperaquine (DHA-PPQ). There is such a low risk of sudden unexpected death from DHA-PPQ, one of the world’s most effective medicines to treat malaria, that there is no need to limit its current use.

8 June Bangkok (Thailand) – One of the world’s most widely used anti-malarial drugs is safe to use, say researchers, after a thorough review and analysis of nearly 200,000 malaria patients who’d taken the drug dihydroartemisinin-piperaquine (DHA-PPQ).

There is such a low risk of sudden unexpected death from DHA-PPQ, one of the world’s most effective medicines to treat malaria, that there is no need to limit its current use, the researchers say in a study published today in The Lancet Infectious Diseases.

"There had been some concerns that DHA-PPQ could be toxic for the heart. This very large study provides reassurance about the safety of one of our most important antimalarial drugs," said study co-author University of Oxford Prof Sir Nick White.

Used to treat P. falciparum and P. vivax malaria in Africa and Asia and in large-scale pilot programmes to eliminate malaria, DHA-PPQ is a highly efficacious and well-tolerated oral artemisinin combination treatment (ACT) medication that is on the WHO’s List of Essential Medicines. Although DHA-PPQ has been used to treat more than 5.4 million people since its use was approved in Europe in 2011, there were concerns its use could lead to potentially lethal heart arrhythmias and sudden cardiac death.

After carefully examining 96 studies, totalling 197,867 people who’d taken DHA-PPQ, researchers found one potentially drug-related sudden death. They concluded that the risk of sudden unexplained death after DHA-PPQ was no higher than the baseline rate for sudden cardiac death in the general population – and therefore  that there was no reason to limit the use of DHA-PPQ.

“This analysis of almost 200,000 malaria patients treated with DHA-PPQ provides the definite answer and reassuring message that the cardiac effects of piperaquine are not related to life threatening cardiac events and that DHA-PPQ is very safe to use," said University of Oxford Prof Arjen Dondorp, Deputy Director of the Bangkok-based Mahidol Oxford Tropical Medicine Research Unit (MORU).

“This study is important: It clearly shows no evidence of increased cardiac mortality associated with DHA-PPQ therapy in large population studies. It certifies the safety of using DHA-piperaquine as a preventive strategy. The next step should be prospective studies to confirm these very reassuring results," said cardiologist and study co-author Prof Josep Brugada of the University of Barcelona.

The study results were hailed by people active in the global fight against malaria, a parasitic disease transmitted by mosquitoes that killed 445,000 people in 2016, most of them children in Africa.

Michael Chew, from Wellcome's Infection and Immunobiology team, said: "DHA-PPQ is one of the most effective and widely used anti-malarial drugs we have today, and concerns it could lead to heart attacks risked limiting its use and impact. This important study confirms that this drug is safe to use, as the risk of sudden cardiac death in patients is the same as in the general population."

Similar stories

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU Bangkok Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments MORU Bangkok

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU Bangkok Research

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

MORU Bangkok Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.

Applicability of COVID-19 vaccine trial results to low-and-middle-income countries

COVID-19 MORU Bangkok

In the next few months, the first Phase 3 COVID-19 vaccine trials – the majority of them in upper-middle or high-income countries and in specific target populations like young adults – will report their results. How relevant will their study results be for low-resource settings?

Congratulations new NDM professors

Awards & Appointments LOMWRU MORU Bangkok

The University of Oxford has awarded CTMGH two new Professors. Elisabeth Ashley - UK-trained physician who specialises in infectious diseases and medical microbiology & virology, and Director of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) in Lao PDR since 2019, Liz is conferred the title of Professor of Tropical Medicine. Stuart Blacksell - Senior Research Scientist based at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Thailand, Stuart is conferred the title of Professor of Tropical Microbiology.